---
title: "Galectin Therapeutics posts corporate presentation highlighting belapectin program for MASH cirrhosis, portal hypertension"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292638312.md"
description: "Galectin Therapeutics plans to file a Phase 3 protocol for belapectin in MASH cirrhosis with portal hypertension by Q3 2026. The NAVIGATE trial showed reduced varices incidence but missed statistical significance on the primary endpoint. The company continues focusing on belapectin, which holds Fast Track status, and has FDA clearance to proceed with oncology combinations in head and neck cancer."
datetime: "2026-07-14T13:53:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292638312.md)
  - [en](https://longbridge.com/en/news/292638312.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292638312.md)
generator: "portal-rs"
---

# Galectin Therapeutics posts corporate presentation highlighting belapectin program for MASH cirrhosis, portal hypertension

-   Galectin Therapeutics outlined plans to file a Phase 3 protocol in Q3 2026 for belapectin in MASH cirrhosis with portal hypertension. \* NAVIGATE Phase 2b/3 trial completed; per-protocol varices incidence fell to 11.3% on belapectin 2 mg vs 22.3% on placebo (p=0.04). \* Intent-to-treat composite primary endpoint missed statistical significance (p=0.13 for 2 mg; p=0.55 for 4 mg). \* Pipeline focus remains belapectin, a galectin-3 inhibitor with Fast Track status, targeting portal hypertension where no approved reversal therapies exist. \* Oncology program highlighted belapectin with Keytruda; clinical activity cited in checkpoint combinations, with FDA clearance to proceed in head and neck cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GALT.US](https://longbridge.com/en/quote/GALT.US.md)

## Related News & Research

- [Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension](https://longbridge.com/en/news/290558546.md)
- [Galectin, FDA agree on late-stage trial design for MASH therapy](https://longbridge.com/en/news/290567199.md)
- [PFSE: Record Q2 revenue and profit growth, driven by strong demand and innovation in HVDC technology](https://longbridge.com/en/news/296308264.md)
- [SSE wins local approval for Cambushinnie 400kV substation near Braco](https://longbridge.com/en/news/296584916.md)
- [Cereno Scientific activates first site for Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension](https://longbridge.com/en/news/295750138.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**